Piramal Life Sciences (PLSL), the recently demerged drug research division of Nicholas Piramal India (NPIL), will get listed on the Bombay stock Exchange (BSE) tomorrow.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>The company had issued 1 share of the new company for every 10 of the parent company. Nicholas Piramal will hold 18 per cent of new company and 82 per cent will be held by NPIL shareholders. </P>
</p><p class='TableClas'>Nicholas Piramal also transfered Rs 95 crore of assets to the new company. PLSL is focused on four therapeutic areas 

Piramal Life Sciences to get listed on BSE

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News